Ignite Creation Date:
2024-05-06 @ 2:59 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04488705
Status:
COMPLETED
Last Update Posted:
2021-05-21
First Post:
2020-07-23
Brief Title:
A First in Human Study to Evaluate the Safety Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
Sponsor:
Enterprise Therapeutics Ltd
Organization:
Enterprise Therapeutics Ltd
Study Overview
Official Title:
A First in Human Randomised Double Blind Placebo-controlled Three-part Study to Evaluate the Safety Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses SAD MAD of Inhaled ETD002 in Healthy Male and Female Subjects
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first in human study of ETD002 a new drug being developed for the treatment of cystic fibrosisThe study is a randomised double-blind placebo-controlled interventional study to assess the safety and tolerability of ascending single and repeat doses of inhaled ETD002 in healthy male and female subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-001080-92 | EUDRACT_NUMBER | None | None |